TriSalus Life Sciences, Inc.

TLSI

CIK 0001826667 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$13M
↑+59.8% +$5Mvs FY2024 (Q4)
Operating Income
$9M
↑+124.7% +$5Mvs FY2024 (Q4)
Net Income
$7M
↑+158.2% +$4Mvs FY2024 (Q4)
Gross Profit
$11M
↑+62.4% +$4Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Excellent
100/100
  • Profitability
    100ROIC 920.5% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 2.80 (above 1.5 = solid)
  • Leverage
    100D/E -0.98 (under 0.5 = conservative)
  • Efficiency
    100Asset Turnover 1.52x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +59.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -77.9% · trend +62.5pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$1M
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$9M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$35M
everything owned
Total liabilities
$69M
everything owed
Stockholders' equity
$-34M
shareholder claim
Net debt
$13M
LT debt minus cash

Recent performance · 21 quarters

Revenue↑+59.8% +$5M
$13M
Net Income↓-350.6% -$8M
$-11M
Free Cash Flow↑+18.0% +$9K
$-41K
Operating Margin↑+41.0pts
-77.9%

Drill down